Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: A systematic review

Current Opinion in Pulmonary Medicine

Volumn 10, Issue 5, 2004, Pages 338-344

  Nijkeuter, M ^a   Huisman, M V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fondaparinux; Pentasaccharides; Selective anti Xa inhibitors; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; PLACEBO; WARFARIN;

BLEEDING; CLINICAL TRIAL; DISEASE EXACERBATION; HIP FRACTURE; HUMAN; INCIDENCE; KNEE SURGERY; LUNG EMBOLISM; MORBIDITY; ORGAN BLOOD FLOW; ORTHOPEDIC SURGERY; PROPHYLAXIS; REVIEW; SIDE EFFECT; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 4143117812     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcp.0000136901.80029.37     Document Type: Review

References (20)

1. Barritt DW, Jordan SC: Anticoagulant drugs in the treatment of pulmonary embolism. Lancet 1960, 1:1309-1312.
2. Quinlan DJ, McQuillan A, Eikelboom JW: Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004, 140:175-183.
3. Warkentin TE, Levine MN, Hirsh J, et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
4. Schulman S: Unresolved issues in anticoagulant therapy. J Thromb Haemost 2003, 1:1464-1470.
5. Coussement PK, Bassand JP, Convens C, et al.: A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study. Eur Heart J 2001, 22:1716-1724.
6. Vuillemenot A, Schiele F, Meneveau N, et al.: Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999, 81:214-220.
7. Turpie AG, Gallus AS, Hoek JA: A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001, 344:619-625.
8. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators. Circulation 2000, 102:2726-2731.
9. The Persist Investigators: A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a Phase II evaluation. J Thromb Haemost 2004, 2:47-53.
10. Lassen MR, Bauer KA, Eriksson BI, et al.: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002, 359:1715-1720. A well-designed phase III prophylaxis study in patients undergoing major orthopedic surgery, evaluating fondaparinux versus standard comparator LMWH.
11. Turpie AG, Bauer KA, Eriksson BI, et al.: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002, 359:1721-1726. See [10•].
12. Bauer KA, Eriksson BI, Lassen MR, et al.: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001, 345:1305-1310. See [10•].
13. Eriksson BI, Bauer KA, Lassen MR, et al.: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001, 345:1298-1304. See [10•].
14. Eriksson BI, Bauer KA, Lassen MR, et al.: Influence of the duration of fondaparinux (Arixtra) prophylaxis in preventing venous thromboembolism following major orthopedic surgery. J Thromb Haemost 2003, 1:383-384.
15. The Matisse Investigators: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Int Med 2004, 140:867-873.
16. Buller HR, Davidson BL, Decousus H, et al.: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349:1695-1702. A well-designed large clinical trial evaluating fondaparinux versus unfractionated heparin in the initial treatment of patients with pulmonary embolism. One of the few well-designed large studies in this area.
17. Bounameaux H, Perneger T: Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet 2002, 359:1710-1711.
18. Davidson BL: What are the most reliable detection methods for deep vein thrombosis and pulmonary embolism to be used as endpoints in trials of venous thromboprophylaxis? Haemostasis 1998, 28(Suppl 3):113-119.
19. Kearon C, Julian JA, Math M, et al.: Noninvasive diagnosis of deep venous thrombosis. Ann Intern Med 1998, 128:663-677.
20. Cohen AT, Bailey CS, Alikhan R, et al.: Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost 2001, 85:940-941.